Home Alzheimer’s Disease Planned Phase III Trial of Ruxolitinib Plus Standard-of-Care for Patients with COVID-19

Planned Phase III Trial of Ruxolitinib Plus Standard-of-Care for Patients with COVID-19

Incyte announced that they are working in partnership with the FDA to initiate a phase III clinical trial to evaluate the efficacy and safety of ruxolitinib (Jakafi) plus standard-of-care (SoC), compared to SoC therapy alone, in patients with coronavirus disease 2019 (COVID-19) induced cytokine storm.1

The global collaborative study, titled RUXCOVID, will be sponsored by Incyte in the US, and Novartis outside of the US. 

Moreover, Incyte is also expecting to initiate a separate open-label emergency Expanded Access Program (EAP) in the US. The protocol will allow patients who are eligible with severe COVID-19 associated cytokine storm to receive ruxolitinib while it is being investigated for this indication. 

“Our intent is to build on emerging evidence from independent studies to further establish the role ruxolitinib could play in balancing immune response to the infection and…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

I put my feelings in music. : braincancer

Song LinkHi amigos. My 2year old son has been battling cancer for nearly 6 months and this song is just a expression of my...

Recent Comments